Funding for this research was provided by:
Ampio Pharmaceuticals, Inc
Text and Data Mining valid from 2018-06-18
Received: 16 April 2018
Accepted: 20 April 2018
First Online: 18 June 2018
Ethics approval and consent to participate
: The study was approved from the Schulman Institutional Review Board with documentation of informed consent.
: Dr. Bar-Or reports personal fees from Ampio Pharmaceuticals Inc., during the conduct of the study; In addition, Dr. Bar-Or has 120 issued patents and 80 pending. Dr. Bar-Or is an employee of Ampio Pharmaceuticals, Inc. and serves as the chief Scientific officer of Ampio Pharmaceuticals and own stocks and stock options in the company. Ampio is developing LMWF-5A for the treatment of OA of the knee. Mrs. Salottolo reports personal fees from Ampio Pharmaceuticals, Inc., and own stocks and stock options in the company. Dr. Cole reports conflicts outside the submitted work including: personal fees and other from Arthrex, other from Arthroscopy; other from Aesculap/B.Braun, other from American Journal of Orthopedics, other from American Orthopaedic Society for Sports Medicine, other from American Shoulder and Elbow Surgeons, personal fees and other from Arthrex, Inc., other from Arthroscopy Association of North America, other from Athletico, other from Carticept, other from Cytori, other from DJ Orthopaedics, other from Elsevier Publishing, other from International Cartilage Repair Society, other from Journal of Bone & Joint Surgery - American, other from Journal of Shoulder and Elbow Surgery, other from Journal of the American Academy of Orthopaedic Surgeons, other from Medipost, other from National Institutes of Health (NIAMS & NICHD), other from Ossur, personal fees and other from Regentis, other from Saunders/Mosby-Elsevier, other from Smith & Nephew, other from Tornier, personal fees and other from Zimmer, other from Arthroscopy.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.